title: Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in hip fracture surgery.
abstract: Hip fracture patients are at high risk of developing venous thromboembolic events (VTEs) postoperatively. Efficacy and safety data from a clinical trial comparing fondaparinux and enoxaparin as VTE prophylaxis were used to perform a cost assessment of these 2 agents. Incremental cost calculations demonstrate that enoxaparin offers advantages over fondaparinux when dosed for 7 days postoperatively in this patient population. Sensitivity analyses support this finding at the lower extreme; however, fondaparinux provides cost savings at the upper extreme. Cost per death averted and cost per life year gained are similar for these 2 agents in these patients.
authors.affiliation: Department of Clinical and Administrative Pharmacy, College of Pharmacy University of Georgia, Athens, Georgia 30602-2354, USA. bwade@mail.rx.uga.edu
authors.forename: William E
authors.initials: WE
authors.lastname: Wade
authors.forename: William J
authors.initials: WJ
authors.lastname: Spruill
authors.forename: Ryan B
authors.initials: RB
authors.lastname: Leslie
mesh_terms: D000925:Anticoagulants / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D017984:Enoxaparin / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D000077425:Fondaparinux; D006620:Hip Fractures / Q000601:surgery*; D006801:Humans; D008017:Life Expectancy; D008297:Male; D011134:Polysaccharides / Q000191:economics / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000191:economics / Q000401:mortality / Q000517:prevention & control; D020246:Venous Thrombosis / Q000191:economics / Q000401:mortality / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D011134:Polysaccharides; D000077425:Fondaparinux